Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India
Article in JCO Global Oncology (February 2024)
The most recent citing publications are shown below. View all 10 publications that cite this research output on Dimensions.
Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China
Article in Clinical Medicine Insights Oncology (January 2024)
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece
Article in Expert Review of Pharmacoeconomics & Outcomes Research (November 2023)